

How μ -Opioid Receptor Recognizes Fentanyl

Quynh N. Vo,^{†,‡} Paween Mahinthichaichan,^{†,‡} Jana Shen,^{*,‡} and Christopher R. Ellis^{*,†}

[†] Center for Drug Evaluation and Research, United State Food and Drug Administration, Silver Spring, Maryland 20993

[‡] Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, Baltimore, Maryland 21201

Received November 25, 2020; E-mail: Jana.Shen@rx.umaryland.edu; Christopher.Ross.Ellis@gmail.com

Abstract: In 2019, drug overdose has claimed over 70,000 lives in the United States. More than half of the deaths are related to synthetic opioids represented by fentanyl which is a potent agonist of mu-opioid receptor (mOR). In recent years, the crystal structures of mOR in complex with morphine derivatives have been determined; however, structural basis of mOR activation by fentanyl-like synthetic opioids remains lacking. Exploiting the X-ray structure of mOR bound to a morphinan ligand and several state-of-the-art simulation techniques, including weighted ensemble and continuous constant pH molecular dynamics, we elucidated the detailed binding mechanism of fentanyl with mOR. Surprisingly, in addition to forming a salt-bridge with Asp147^{3,32} in the orthosteric site common to morphinan opiates, fentanyl can move deeper and bind mOR through hydrogen bonding with a conserved histidine His297^{6,52}, which has been shown to modulate mOR's ligand affinity and pH dependence in mutagenesis experiments, but its precise role remains unclear. Intriguingly, the secondary binding mode is only accessible when His297 adopts a neutral HID tautomer. Alternative binding modes and involvement of tautomer states may represent general mechanisms in G protein-coupled receptor (GPCR)-ligand recognition. Our work provides a starting point for understanding the molecular basis of mOR activation by fentanyl which has many analogs emerging at a rapid pace. The knowledge may also inform the design of safer analgesics to combat the opioid crisis. Current protein simulation studies employ standard protonation and tautomer states; our work demonstrates the need to move beyond the practice to advance our understanding of protein-ligand recognition.

INTRODUCTION

Opioids are highly effective pain relievers, but their addictive nature can easily lead to abuse and overdose-related deaths. From 1999–2018, almost 450,000 people died from opioid overdose in the United States.¹ Overdose deaths from synthetic opioids, represented by fentanyl and its derivatives, are now associated with more deaths than any other type of opioids.² The surge in fentanyl is attributed to high potency (50–400 times more potent than the naturally occurring morphine), fast onset, straightforward synthesis, and low cost production.^{3–6} Additionally, the fentanyl core is readily modified creating a vast chemical space of fentanyl analogs with abuse potential.⁷

Fentanyl and morphine opioids produce strong analgesic responses through binding and subsequent activation of a class A G protein-coupled receptor (GPCR) μ -opioid receptor (mOR).⁸ In recent years, high-resolution crystal structures of mOR in complex with the morphinan agonist BU72,⁹ an-

tagonist β -FNA,¹⁰ as well as the endogenous peptide analog agonist DAMGO¹¹ have been determined, featuring a salt bridge between a charged amine group of the ligand and a conserved residue Asp147 on the transmembrane helix (TM) 3 (Asp^{3,32} in the Ballesteros-Weinstein numbering¹²) of mOR. The morphinan compounds and peptide analog also interact with a conserved His297 on TM6 (His^{6,52}) via water-mediated hydrogen bonds. Mutagenesis studies demonstrated that mutation of either Asp147 or His297 as well as a reduced pH (which presumably protonates His297) decreases the binding affinities for DAMGO and naloxone (antagonist).^{13–15}

Despite the importance, surprisingly little is known about the signaling mechanism of fentanyl and how it interacts with mOR to illicit analgesic response.⁶ It is conceivable that fentanyl and its analogs bind and activate mOR in the same manner as morphinan compounds; however, the structural basis remains lacking. The aforementioned mutagenesis experiments performed to probe the role of Asp147 and His297 were inconclusive due to excessive non-specific binding of fentanyl.¹⁵ Docking^{16,17} and long-timescale molecular dynamics (MD) simulations¹⁸ based on the docked structure of fentanyl in mOR confirmed the stability of the orthosteric binding mode involving the salt bridge with Asp147; however, the role of His297 has not been explored.

Towards understanding the molecular mechanism of mOR activation by fentanyl, here we elucidate the detailed fentanyl-mOR binding mechanism by exploiting a morphinan-bound mOR crystal structure and several state-of-the-art molecular dynamics (MD) methods, including the weighted ensemble (WE) approach^{19–21} for enhanced path sampling and membrane-enabled continuous constant-pH MD (CpHMD) with replica-exchange.^{22–24} The latter method has been previously applied to calculate pK_a 's and describe proton-coupled conformational dynamics of membrane channels²⁵ and transporters.^{23,26,27} Surprisingly, WE path sampling found that when His297 adopts the HID tautomer, fentanyl can move deeper into the mOR and establish an alternative binding mode through hydrogen bonding with His297. CpHMD titration showed that His297 favors the HIE tautomer in the apo mOR; however, interaction with the piperidine amine of fentanyl locks it in the HID tautomer. Additional microsecond equilibrium simulations were conducted to further verify the two binding modes and generate fentanyl-mOR interaction fingerprints. Alternative binding modes and involvement of tautomer states may represent general mechanisms in GPCR-ligand recognition. Our work provides a starting point for understanding how fentanyl activates mOR at a molecular level. Fentanyl analogs that can be significantly more potent and addictive are emerging on the dark market at a rapid pace. The molecular mechanism by which structural modifications alter fentanyl potency and abuse potential

can inform the design of safer analgesics to combat the opioid crisis.

Table 1. Simulation summary.

Name	Type	Starting Configuration		Time (μ s)
		Binding Mode	H297 State	
WE-HIE	WE	D147 salt bridge	HIE	24.3
WE-HID	WE	D147 salt bridge	HID	23.6
CpH-apo	CpHMD	apo active mOR	Dynamic	0.32
CpH-D147	CpHMD	D147 salt bridge	Dynamic	0.32
CpH-H297	CpHMD	H297 hydrogen bond	Dynamic	0.32
MD-D147(HID)	equil. MD	D147 salt bridge	HID	0.5
MD-D147(HIE)	equil. MD	D147 salt bridge	HIE	0.5
MD-D147(HIP)	equil. MD	D147 salt bridge	HIP	0.5
MD-H297(HID)	equil. MD	H297 hydrogen bond	HID	1.0
MD-H297(HIE)	equil. MD	H297 hydrogen bond	HIE	1.0
MD-H297(HIP)	equil. MD	H297 hydrogen bond	HIP	1.0

RESULTS AND DISCUSSION

Fentanyl unbinds from the D147-bound configurations in the presence of HIE297. Following the 115-ns MD to relax the docked fentanyl-mOR complex (details see Methods and Protocols and Fig. S1), we performed WE all-atom MD simulations to explore the detailed binding interactions of fentanyl in mOR. The fentanyl RMSD was used as the progress coordinate. The MD trajectories were produced using the GPU-accelerated PMEMD engine in AMBER18²⁸ and the Python-based WESTPA tool²⁰ was used to control the WE protocol.

In the first WE simulation of 24 μ s aggregate time, His297 was fixed in the HIE tautomer ($N\epsilon$ atom of imidazole is protonated), as in the recent mOR simulations by the Dror group.^{9,11} The WE-HIE simulation proceeded as expected. In the first 75 iterations or 2.5 μ s of cumulative sampling time, fentanyl's piperidine stays near Asp147, sampling both the salt-bridged and solvent-separated configurations, with the FEN–D147 distance (minimum heavy-atom distance between the piperidine amine and the carboxylate) below 5 Å (Fig. 2A and Fig. S2B). During this time, fentanyl ΔZ fluctuates between 7.5 and 10.5 Å (Fig. S2D), and RMSD stays below 4 Å (Fig. S2A). ΔZ is defined as the distance between the centers of mass of fentanyl and mOR in the z direction, whereby the N- (52–65) and C-terminal (336–347) residues of mOR were excluded from the calculation. After 75 iterations, fentanyl starts to move upward and away from Asp147; after about 140 iterations or 8 μ s of cumulative sampling time, RMSD increases to above 7.5 Å and ΔZ starts to sample values above 14 Å, indicating that fentanyl is on the way to exit mOR (Fig. S2A-C). At the end of 300 iterations or 24 μ s of cumulative sampling time, fentanyl reaches the extracellular end of mOR (Fig. S2D). It is noteworthy that in the WE-HIE simulation, the FEN–H297 distance from the piperidine nitrogen to the unprotonated imidazole nitrogen is always above 4 Å, indicating that fentanyl's piperidine does not form hydrogen bond interactions with His297 (Fig. 2A and Fig. S2C). Interestingly, even with the intact piperidine–D147 salt bridge, fentanyl can sample various configurations with a RMSD as high as 8 Å (Fig. S2A,B).

Fentanyl samples both D147- and H297-bound configurations in the presence of HID297. In addition to HIE, a neutral histidine can adopt the HID tautomer state, whereby the $N\delta$ atom is protonated. Considering the important and yet unclear role of His297 in opioid-mOR binding, we conducted another WE simulation with His297 fixed in HID (WE-HID).

Surprisingly, fentanyl did not exit mOR as was observed in the WE-HIE simulation. After about 27 iterations or 0.6 μ s of cumulative sampling time, some of the trajectories start to sample configurations in which fentanyl laterally rotates 120°, translates 2 Å, and moves down 1 Å, enabling the formation of a stable hydrogen bond between the piperidine amine and the unprotonated $N\epsilon$ atom of HID297, (Fig. 1A, Fig. 2B, and Fig. S3). At the same time, the RMSD remains below 7 Å. Unexpectedly, after about 210 iterations or 13 μ s of cumulative sampling time, some trajectories start to sample configurations in which fentanyl is inserted deeper into the receptor (Fig. S3D). At the end of 20 μ s aggregate time, fentanyl continues to sample the D147- and HID297-bound configurations along with positions in which it does not interact with either residues (Fig. 2B and Fig. S3); however, the fentanyl ΔZ stay below 14 Å, indicating that it remains inside of the ligand accessible vestibule of mOR (Fig. 2B and Fig. S3D).

Further comparison between the configurations from the WE-HIE and WE-HID simulations. To further understand the differences in the configuration space sampled by fentanyl in the presence of HIE297 and HID297, we plotted FEN–H297 vs. FEN–D147 distance and color coded the data points by ΔZ of fentanyl. Corroborating with the previous analysis, these plots show that while the D147-bound configurations (FEN–D147 distance \leq 3.5 Å) are sampled in both WE-HIE and WE-HID simulations, the H297-bound configurations (FEN–H297 distance \leq 3.5 Å) are only sampled in the WE-HID simulation (Fig. 2C and D). Further, the H297-bound configurations sample lower ΔZ positions of 3–8 Å, as compared to the D147-bound configurations whereby ΔZ is in the range of 7–13 Å, (Fig. 2C-F, and Fig. S3, S4). Interestingly, the WE-HID simulation also sampled fentanyl configurations deeply embedded in mOR ($\Delta Z \leq$ 3 Å) but without a hydrogen bond with HID297 (FEN–H297 distance of 4–6 Å), suggesting that the piperidine–HID297 hydrogen bond may not be the only stabilizing factor for the deep insertion of fentanyl in mOR (Fig. 2D and Fig. S4). Representative snapshots suggest that the interactions between the phenylethyl group and Trp293 may be a contributor (Fig. 2F).

His297 favors the HIE tautomer in the apo mOR but the piperidine–HID297 interaction locks His297 in the HID state. The WE simulations suggest that fentanyl has an alternative binding mode which may be promoted by the presence of the HID tautomer of His297. To determine the physiological relevance, we carried out titration simulations using the membrane-enabled hybrid-solvent CpHMD method with pH replica exchange^{22,23} to determine the protonation state of His297 under physiological pH for the apo mOR and the fentanyl-bound mOR in the D147- as well as the H297-binding modes. For each system, 16 pH replicas were simulated in the pH range 2.5–9.5, with the aggregate sampling time of 320 ns. All Asp/Glu/His and fentanyl's piperidine amine in the holo systems were allowed to titrate. The calculated pK_a of His297 is well converged (Fig. S4).

In the absence of ligand (CpH-apo simulation), the calculated macroscopic pK_a of His297 is 6.8. At physiological pH 7.4, the HIE tautomer is predominantly sampled at 64%, while the HID tautomer and the charged HIP populations are 12% and 24%, respectively (Fig. 3A). The presence of fentanyl in the D147-binding mode upshifts the His297 pK_a to 7.3 (CpH-D147 simulation). At physiological pH, both HIE




Figure 1. Fentanyl binding with mOR. **A.** Overlay of the representative simulation snapshots showing mOR is bound to fentanyl in the D147- (green) and H297- (purple) binding modes. **B.** Zoomed-in view of the D147-binding mode, in which the charged piperidine amine of fentanyl forms a salt bridge with Asp147. **C.** Zoomed-in view of the H297-binding mode, where the piperidine amine donates a proton to N ϵ of HID297. The curved arrow illustrates the change in the orientation of fentanyl in going from D147- to H297-binding mode. mOR residues making significant contacts with fentanyl (fraction greater than 0.5) are shown (see Fig. 4). Those unique to the two binding modes are labeled in red and otherwise in black. **D.** Structure of fentanyl with different substituent groups and the protonated/charged amine labeled. **E.** Histidine protonation states. HID and HIE are neutral while HIP is charged.

and HIP are the predominant forms accounting for 39% and 44% of the population, respectively, while HID accounts for 17% of the population (Fig. 3B).

Finally, CpHMD titration was also performed for the fentanyl-mOR complex in the H297-binding mode (CpH-H297 simulation). Interestingly, the calculated pK_a of His297 is 6.7, nearly the same as for the apo mOR; however, at physiological pH HID is the predominant form with a population of 60%, while the HIE and HIP forms account for 20% each. Importantly, the protonation state of His297 is coupled to its distance to the piperidine amine of fentanyl (Fig. 3D). When the piperidine nitrogen is within 4 Å of the N ϵ atom of His297, the HID state is exclusively sampled, whereas the HIE and HIP states are only allowed when the piperidine-His297 distance is ≥ 7 Å (Fig. 3D). This data is consistent with the equilibrium MD which shows that the distance is 3.0 ± 0.22 Å, 7.4 ± 0.72 Å, and 8.0 ± 0.5 Å with HID297, HIE297, and HIP297, respectively, while the distance range 4–7 Å is rarely sampled (Fig. S8). Note, in both holo simulations the piperidine amine remains protonated/charged in the entire pH range 2.5–9.5.

The CpHMD simulations demonstrate that ligand interaction perturbs the protonation state of His297: while the apo mOR preferably samples HIE297, the population of HIP or HID state may increase upon ligand binding. When fentanyl interacts with Asp147, the HIP state is sampled with an equal

probability as HIE, and when fentanyl interacts with His297, HID is the preferred state. These data provide an explanation as to why the H297-binding mode (quickly) emerged in the WE simulation with HID297 but not HIE297.

Asp114 is deprotonated. The protonation state of the highly conserved residue Asp114 (Asp^{2.50}) in the active mOR remains unclear to this day. Despite not having a direct role in ligand binding, Asp114 is involved in mOR activation.^{9,11,29,30} Previous experiments³⁰ and simulations^{9,11,29} demonstrated that Asp114 binds a sodium ion in the inactive but not active state of GPCRs. Based on the lack of sodium binding, two previous MD studies used a protonated Asp114,^{9,11} while other published work did not specify the protonation state.^{18,31,32} The CpHMD titration gave a pK_a of 4.8 ± 0.30 for the apo and $5.1 \pm 0.26/0.29$ for the fentanyl-bound mOR in the D147- or H297-binding mode. Therefore, even though the pK_a 's are upshifted relative to solution value of 3.8,³³ Asp114 remains deprotonated at physiological pH in the active mOR according to the CpHMD simulations.

The D147-binding mode is stable regardless of the protonation state of H297. To further characterize fentanyl-mOR interactions and delineate the impact of the His297




Figure 2. Fentanyl visits the D147-binding mode in the presence of HIE297 but both D147- and H297-binding modes in the presence of HID297. **A, B.** The FEN--D147 distance, referred to as the minimum distance between the piperidine nitrogen and the carboxylate oxygen of Asp147, as a function of the cumulative WE simulation time in the presence of HIE297 (A) or HID297 (B). Data with the FEN--D147 and FEN--H297 distances below 3.5 Å are colored green and orange, respectively, and otherwise blue. The unweighted data from all bins were taken and the time refers to the cumulative time. The dotted vertical lines are drawn at every 50 WE iterations. **C, D.** FEN--H297 vs. FEN--D147 distance from the WE-HIE (C) and WE-HID (D) simulations. The data points are color coded by the fentanyl ΔZ position, defined as the distance between the centers of mass of fentanyl and mOR in the z direction, whereby the N- (52–65) and C-terminal (336–347) residues of mOR were excluded from the calculation. The FEN--H297 distance is measured between the piperidine nitrogen and the unprotonated imidazole nitrogen of His297. Three groups of data (labeled in the plots) taken from the last 50 iterations of each simulation were subjected to the hierarchical clustering analysis. For WE-HIE, the three groups were defined as FEN--D147 distance ≤ 3.5 Å; FEN--D147 distance ≥ 4 Å and FEN--H297 distance ≤ 8 Å; and FEN--D147 distance ≥ 4 Å and FEN--H297 distance ≥ 8 Å. For WE-HID, the three groups were defined as FEN--D147 distance ≤ 3.5 Å; FEN--H297 distance ≤ 3.5 Å; and FEN--D147 distance ≥ 8.5 Å and FEN--H297 distance ≥ 4 Å. **E, F.** Representative structures of the most populated clusters from the WE-HIE (E) and WE-HID (F) data defined in C and D. The FEN--D147 and --H297 distances and the fentanyl ΔZ position are given.

protonation state, we carried out a series of equilibrium simulations. First, three 0.5- μ s simulations were initiated from the equilibrated fentanyl-mOR complex in the D147-binding mode with His297 fixed in the HID, HIE, and HIP states (Table 1). To quantify ligand-receptor interactions, the fractions of time for the mOR residues that form at least one heavy atom contact with fentanyl were calculated (Fig. 4A-D, top panels). To determine what parts of fentanyl contribute to the receptor recognition, a fingerprint matrix was calculated which shows the contacts formed between specific mOR residues and fentanyl substituents (Fig. 4A-D, bottom panels). Simulations starting from the D147-binding mode demonstrated that many interactions are independent of the protonation state of His297. Most importantly, the piperidine--D147 salt bridge remains stable throughout the 0.5- μ s trajectories with HIE297, HID297, and HIP297 (Fig. S5 and red

bars in Fig. 4A-C), consistent with the WE simulations. Interestingly, while maintaining the salt bridge with piperidine, Asp147 also interacts with phenyl and phenethyl at the same time (Figure 4A-C, bottom panels), which may provide further stabilization to the D147-binding mode.

Another important fentanyl-mOR contact is the aromatic stacking interaction between the phenyl ring of the phenethyl group and Trp293 (Fig. 1B, Fig. 4A-C bottom panels, and Fig. S6), which remains stable in all three simulations. The importance of the phenethyl group at this location in the 4-anilidopiperidine core of fentanyl is supported by the observations that substitution with methyl (as in N-methyl-fentanyl) increases the K_i value by about 40 fold,³⁴ and removal of one ethylene group renders the ligand inactive.³⁵ However, substitution with a different aromatic ring, e.g thiophene in sufentanil and ethyl tetrazolone in alfentanil, does not appear




Figure 3. Protonation state of His297 is influenced by fentanyl binding. **A, B, C.** Occupancies of the HID (green), HIE (orange), and HIP (blue) states of His297 as a function of pH from the replica-exchange CpHMD simulations of the apo mOR (**A**) and fentanyl-bound complex in the D147- (**B**) and H297-binding mode (**C**). The three states are in equilibrium through protonation/deprotonation and tautomerization. **D.** Average distance between the piperidine nitrogen and His297's N ϵ at different pH conditions when His297 is in the HID (green), HIE (orange), or HIP (blue) state. The area of the data point is proportional to the occupancy of the protonation state. A zoomed-in snapshot corresponding to the HID state is shown.

to be have a significant effect on binding affinity, although the latter ligands have an O-methyl group at the 4-axial hydrogen position.⁴ The importance of the phenethyl-Trp293 stacking interaction is also consistent with a recent study which showed that removal of one methylene group from phenethyl increases the IC₅₀ value by two orders of magnitude.³⁶

Fentanyl-mOR interaction profiles vary with different protonation state of His297 albeit in the same D147-binding mode. Despite the similarities, the fentanyl-mOR interaction profiles obtained from the simulations MD-D147(HID), MD-D147(HIE), MD-D147(HIP) show differences (Fig. 4A-C). To quantify the overall difference between two interaction profiles, the Tanimoto coefficient (T_c)³⁷ was calculated (Fig. 5A), where T_c of 1 indicates that identical mOR residues are involved in binding to fentanyl. Accordingly, the contact profiles with HIE297 and HIP297 are more similar (T_c of 0.81), whereas the contact profiles with HID297 and HIE297/HIP297 are somewhat less similar (T_c of 0.71/0.73). As to the latter, the most significant differences are in the N-terminus. While fentanyl makes no contact with the N-terminus in the simulation with HID297, it interacts via propanamide and phenyl groups with His54 and Ser55 in the simulations with HIE297/HIP297. The fentanyl-N-terminus interactions are consistent with an experimental study which

demonstrated that truncation of the mOR N-terminus increases the dissociation constant of fentanyl by 30 fold.³⁸ Significant differences are also seen in the TM2 contacts between simulations with HIE297 and HID297/HIP297. Four TM2 residues, Ala113, Asp114, Ala117, Gln124, are involved in stable interactions with fentanyl in the simulations with HID297/HIP297; however, only one TM2 residue Gln124 contacts fentanyl in the simulation with HIE297 (Fig. 4A-C, top panels). A closer examination revealed that Gln124 interacts with phenyl in the simulation with HID297/HIP297 but it additionally interacts with propanamide in the simulation with HIE297, forming a stable hydrogen bond (Fig. 4A and B, bottom panels, Fig. S7A and B). This hydrogen bond may contribute to an upward shift of fentanyl's position in the simulation with HIE297 (see later discussion), resulting in a decrease of the aromatic stacking interaction between the phenyl ring of the phenethyl group and Trp293 (Fig. S6D).

The H297-binding mode is stabilized by many fentanyl-mOR contacts in the presence of HID297. To further evaluate the fentanyl-mOR interactions in the H297-binding mode, three 1- μ s equilibrium simulations were initiated from the H297-binding mode with His297 fixed in the HID, HIE, and HIP states. We refer to these simulations as MD-H297(HID), MD-H297(HIE) and MD-H297(HIP), respectively (Table 1). In the MD-H297(HID) simulation, the piperidine-H297 hydrogen bond remains stable; however, the hydrogen bond immediately breaks and the N-N ϵ distance fluctuates around 7.5 Å and 8.0 Å in the simulations with HIE297 and HIP297, respectively (Fig. S8). These results are in agreement with the CpHMD titration, confirming that the H297-binding mode is only stable in the presence of HID297. In addition to the piperidine-H297 hydrogen bond, the simulation MD-H297(HID) shows that fentanyl forms stable contacts (with a contact fraction greater than 0.5) with over a dozen of residues on TM3, TM5, TM6, and TM7 (Fig. 1C and Fig. 4D), which explains the stability of the H297-binding mode in both MD-H297(HID) and WE-HID simulations.

Comparison of the fentanyl-mOR contact profiles in the two binding modes. Several interactions, e.g., stable contacts with Met151 (TM3), Trp293 (TM6), and Ile322 (TM7), are shared among all equilibrium simulations, regardless of the binding mode or His297 protonation state (Fig. 1B and C, Fig. 4A-D). Among them is the aromatic stacking between the phenethyl group and Trp293 (Fig. 4A-D, Fig. S6), which is stable in all simulations. Nonetheless, the contact profile from the simulation MD-H297(HID) is drastically different from those in the D147-binding mode. The T_c value comparing MD-H297(HID) with MD-D147(HID), MD-D147(HIE), and MD-D147(HIP) are 0.44, 0.46 and 0.31, respectively (Fig. 5A). Fentanyl contacts with the N terminus and TM2 residues are completely absent and fewer TM7 residues are involved in fentanyl interactions in the simulation MD-H297(HID) (Fig. 4D). Most contacts uniquely observed for the H297-binding mode involve TM5 residues. As His297 is slightly below Asp147, a switch from the piperidine-D147 salt bridge to the piperidine-H297 hydrogen bond results in a lower vertical position for fentanyl as compared to the D147-binding mode. The change in the vertical position likely contributes to the differences in the mOR residues interacting with fentanyl.

The fentanyl-H297 interactions also appear to perturb the




Figure 4. Fentanyl-mOR interaction profiles in the presence of different protonation state of His297 and comparison to the BU72-mOR contacts in the crystal structure. **A-D Top.** Fraction of time that mOR residues form contacts with fentanyl in the equilibrium MD starting from the D147- (**A**, **B**, **C**) and H297-binding modes (**D**). A contact is considered formed if any sidechain heavy atom is within 4.5 Å of any fentanyl heavy atom. Only residues that form contacts for least 25% of the time in at least one of the six equilibrium simulations are shown. Contacts with Asp147, Trp293, and His297 are highlighted in red. **A-D Bottom.** Ligand-mOR fingerprint matrix showing the fentanyl groups as rows and mOR residue as columns. 1 represents in contact and 0 represents no contact. **E.** mOR residues forming contacts with BU72 in the crystal structure (PDB: 5C1M⁹). **F.** Chemical structure of fentanyl and BU72. Different substituent groups are labeled. The 4-axial hydrogen and amine nitrogen of the piperidine group are indicated.

local environment. While the backbone amide-carbonyl hydrogen bond between His297 and Trp293 is present in all equilibrium simulations, the backbone carbonyl of Trp293 also accepts a stable hydrogen bond from the N δ atom of HID297 in the simulation MD-H297(HID) (Fig. S7A and C). We hypothesize that the hydrogen-bond network (fentanyl-HID297-Trp293) together with the aromatic stacking between the phenethyl group and Trp293 contributes to a slight increase in the χ_2 angle of Trp293 ($125 \pm 9.0^\circ$), as compared to that in the D147-binding mode simulations ($112 \pm 10^\circ$ with HIE297, $116 \pm 9.6^\circ$ with HID297, and $110 \pm 9.5^\circ$ with HIP297). Interestingly, the χ_2 angle of Trp293 in the X-ray structure of active mOR bound to BU72 (PDB: 5C1M⁹) is 120° , while that in the X-ray structure of the inactive mOR bound to the antagonist β -FNA (PDB: 4DKL¹⁰) is 80° .

Another intriguing feature of the simulation MD-H297(HID)

is the transient contact between Asp147 and the 4-axial hydrogen of the piperidine ring (Fig. 4D and F). In the simulations of the D147-binding mode, the 4-axial hydrogen makes contact with TM6 or TM7 residues (Fig. 4A-C); however, in the simulation of the H297-binding mode, since the piperidine position is lower due to hydrogen bonding with His297, the 4-axial hydrogen position is also lowered, enabling an interaction with Asp147. Thus, we hypothesize that a substitution for a larger polar group at the 4-axial position might add stable interactions to both the D147- and H297-binding modes, which would potentially explain the increased binding affinity of fentanyl analogs with a methyl ester substitution at the 4-axial position, e.g. carfentanil and remifentanil.^{3,34,36,39}

Comparison of the position and conformation of fentanyl in different binding modes. The WE simulations




Figure 5. Contact similarity and spatial relationship between the D147- and H297-binding modes. **A.** Tanimoto coefficients (T_c) calculated using the binary contacts (details see Methods and Protocols). T_c ranges from 0 to 1, where 1 indicates identical mOR residues are involved in fentanyl binding in both simulations. **B, C.** Locations of fentanyl (stars) and critical amino acids (circles) plotted on the (Y,Z) and (X,Y) planes. A data point is sampled every 10 ns. The center of mass of mOR is set to origin. The data from MD-D147(HID), MD-D147(HIE), and MD-D147(HIP) are colored light green, orange, and blue, respectively, while the data from MD-H297(HID) are colored dark green. The z axis is the membrane normal.

demonstrated that the two fentanyl binding modes are readily accessible from one another in the presence of HID297 (Fig. 2D). The equilibrium simulations found that fentanyl contacts His297 in the D147-binding mode with HID297 or HIE297 (Fig. 4A and B) and it transiently interacts with Asp147 in the H297-binding mode with HID297 (Fig. 4D). To quantify the spatial relationship between the two binding modes, we calculated the center of mass (COM) positions of fentanyl and key contact residues relative to that of mOR based on the equilibrium simulations of the D147- and H297-binding modes and plotted in the (Y,Z) and (X,Y) planes. The resulting side (Fig. 5B) and top (Fig. 5C) views of the fentanyl and mOR residue locations showed that fentanyl adopts a similar position in the simulations of the D147-binding mode with HIE297 or HIP297; however, intriguingly, with HID297, the fentanyl position is moved towards the position it takes in the simulation of the H297-binding mode. Specifically, in going from the D147- to the H297-binding mode, fentanyl laterally rotates by about 120° such that the piperidine amine faces the N_ϵ atom of His297, and translates by about 2 \AA on the (X,Y) plane before moving down the Z axis (Fig. 5B and C). The simulation MD-H297(HID) gave the fentanyl ΔZ of $7.4 \pm 0.4 \text{ \AA}$, as compared to 8.3 ± 0.4 , 8.8 ± 0.3 , and 9.2 ± 0.5 from the simulations MD-D147(HID), MD-D147(HIE), and MD-D147(HIP), respectively. Additionally, fentanyl is in a more upright position in the simulation of the H297 binding mode, with a vertical angle of 15° , compared to the angle of $20\text{--}40^\circ$ in the simulations of the D147

binding mode (Fig. S10).

A closer look at the conformation of His297 suggests that its χ_2 dihedral angle may be modulated by the protonation/tautomer state (Fig. S11). When His297 is in the HIE or HIP state, only the negative χ_2 angle is sampled regardless of the binding mode; however, in the presence of HID297, the simulation of the D147-binding mode samples both negative and positive χ_2 angles, whereas the simulation of the H297-binding mode only samples the positive χ_2 angle. Thus, it is possible that HID297 allows both rotameric states, while the piperidine-H297 hydrogen bond locks the angle at 100° . This data further supports the notion that the two binding modes are made accessible to one another in the presence of HID297.

Comparison to the crystal structures of mOR in complex with BU72 and other ligands. Finally, we compare the two fentanyl binding modes to the crystal structure of the BU72-bound mOR, which was used as a template to build the initial structure of fentanyl-mOR complex for WE simulations. The BU72-mOR binding profile is most similar to fentanyl's D147-binding profile in the presence of HIE297 (T_c of 0.71) due to their nearly identical interactions with the N-terminus, TM2 and TM3 and TM7. To a lesser extent, the BU72 binding profile shares similarities with fentanyl's D147-binding profile in the presence of HID297 or HIP297 (T_c of 0.57 for both). Importantly, the six residues, Gln124 (TM2), Asp147 and Met151 (TM3), Trp293 (TM6), Ile322 and Tyr326 (TM7), which form the foundation of the D147 binding pocket for fentanyl (with contact fraction greater than 0.5 regardless of the protonation state of His297) are present in the BU72-mOR binding contacts (Fig. 4A-C). In contrast, the BU72-mOR contact profile has a much lower overlap with fentanyl's H297-binding profile (T_c of 0.38). In addition to BU72, we compare fentanyl's D147-binding profile (HIE297) to DAMGO- and β -FNA contacts with mOR based on the crystal structures (Fig. S13). In contrast to fentanyl and BU72, DAMGO (a natural agonist) and β -FNA (an antagonist) do not form contacts with TM2 in the crystal structures. Other than that, DAMGO-mOR contact profile is similar to BU72-mOR and fentanyl's D147-binding profile (with HIE297), whereas β -FNA makes additional contacts with TM6 (Ala287, I290, and V291) and has different contacts with TM7.

CONCLUDING DISCUSSION

In summary, a set of state-of-the-art molecular dynamics simulations have been applied to investigate fentanyl binding to mOR. The WE simulations confirmed that fentanyl binds to mOR via the salt-bridge interaction between the piperidine amine and the conserved Asp147, consistent with the X-ray crystal structures of mOR in complex with BU72, β -FNA, and DAMGO.⁹⁻¹¹ However, surprisingly, when His297 is protonated at δ nitrogen (HID), fentanyl can also adopt a H297-binding mode, in which the piperidine amine donates a hydrogen bond to the ϵ nitrogen of HID297. The conventional single trajectory simulations confirmed that the D147-binding mode is stable regardless of the protonation state of His297, whereas the H297-binding mode is only compatible with HID297. These findings are consistent with a recent conventional MD study of the fentanyl-mOR binding, which found that the D147 binding mode was stable in the presence of HID297¹⁸ but fentanyl moved deeper to contact HID297

in some trajectories (personal communication with Lipiński). Our CpHMD titration rationalized the finding by showing that in the absence of the piperidine amine-imidazole interaction, His297 can titrate via either $N\delta$ or $N\epsilon$; however, in the presence of the interaction, $N\epsilon$ loses the ability to gain a proton, locking histidine in the HID form.

We note that calculation of the relative stability of the D147- vs. H297-binding mode is beyond the scope of the present work. Such a study would require converged WE simulations and accurate force field for quantifying the strengths of salt bridges and hydrogen bonds. Previous work by us²⁵ and others⁴⁰ showed that the CHARMM36⁴¹ or the CHARMM36m force field⁴² used in this work overstabilizes salt bridges formed by aspartates, although this might not be the case for the piperidine-Asp147 interaction. Overstabilization of salt bridges is a common problem with additive force fields, which may be overcome by explicit or implicit consideration of polarization.⁴⁰ We also note that given converged WE simulations, the transition rate between the two binding modes may be estimated,⁴³ which is a topic of future exploration.

It is important to consider the physiological relevance of the H297-binding mode. According to the CpHMD titration, at physiological pH, HIE297 is the predominant form in the apo mOR, and HID297 is least populated in both the apo and holo mOR in the D147-binding mode. Consistent with this data, the crystal structure based BU72-mOR contact profile bears the strongest resemblance to the simulated D147-binding mode with HIE297 as compared to HID297 or HIP297. Thus, we hypothesize that fentanyl primarily binds mOR via the D147 mode under physiological pH, while the H297-binding mode is a secondary state. This hypothesis is consistent with the recent experiments^{15,44,45} showing that acidic pH has a negligible effect on fentanyl-mOR binding. These experiments also showed that fluorinated fentanyl which have lower pK_a 's (6.8–7.2) than fentanyl (~8.9^{46,47}) have increased affinities for mOR at lower pH. The CpHMD simulations showed that fentanyl's piperidine amine remains protonated/charged up to pH 9.5, while Asp147 is deprotonated with an estimated pK_a of 3–4. Thus, our data is consistent with the hypothesis^{44,45,48} that while fentanyl's D147-binding is not affected, lowering pH promotes protonation of the fluorinated fentanyls and thereby strengthening the salt bridge with Asp147. We expect the fluorinated fentanyls to have a lower potential for the His297-binding mode at physiological pH than fentanyl due to the decreased protonation of the piperidine.

The X-ray structures of mOR in complex with BU72, β -FNA, and DAMGO^{9–11} show that while the piperidine amine forms a salt bridge with Asp147, the phenol hydroxyl group of the ligand forms a water-mediated hydrogen bond with His297. MD simulations of Dror and coworkers confirmed the stability of the water-mediated interactions between BU72 or DAMGO and His297 (HIE).^{9,11} Simulations of Carloni and coworkers³¹ found that while in the D147-binding mode, the phenol group of morphine or hydromorphone forms a direct or water-mediated hydrogen bond with His297 (HIE), respectively. Morphine was also suggested to make hydrophobic contacts with His297 (HID) while in the D147-binding mode by the recent MD study of Lipiński and Sadlej.¹⁸ The de novo binding simulations of the Filizola group³² showed that oliceridine (TRV-130) which has an atypical chemical scaffold binds mOR via water-mediated interactions with Asp147, while frequently contacting His297 (protonation state unclear). Fentanyl does not have a phenol group, and it differs from mor-

phinan ligands in several other ways. Fentanyl has an elongated shape; it is highly flexible with at least seven rotational bonds; and it has only two structural elements capable of forming hydrogen bonds (amine and carbonyl groups). In contrast, morphinan ligands are bulkier, rigid, and possess more structural elements (i.e. phenol group) with hydrogen bonding capabilities. The bulkier structure and additional hydrogen bond interactions may further stabilize the piperidine-D147 salt bridge, preventing the ligand from moving deeper into mOR and access the H297-binding mode. Therefore, it is possible that the H297-binding mode is unique to fentanyl and analogs. Intriguingly, a combined MD and experimental study found that unlike synthetic antagonists, the endogenous agonist acetylcholine (a small elongated molecule) can diffuse into a much deeper binding pocket of M3 and M4 muscarinic acetylcholine receptors.⁴⁹ Thus, alternative binding modes may be a general phenomenon of GPCR-ligand recognition.

The CpHMD titration allowed us to determine the protonation states of His297 and all other titratable sites in mOR, including the conserved Asp114^{2,50}. Sodium binding in the inactive mOR suggests a deprotonated Asp114,³⁰ while the protonation state for the active mOR remains unclear. Recently, the pK_a of the analogous Asp^{2,50} in M2 muscarinic acetylcholine receptor (m2R) was calculated using the Poisson-Boltzmann method with a protein electric constant of 4.⁵⁰ The calculation gave a pK_a of 8–12 when sodium is 5 Å away from Asp^{2,50}. However, it is widely known that the continuum-based Poisson-Boltzmann methods overestimate the pK_a 's of internal residues, particularly with a low dielectric constant (e.g., 4).⁵¹ The CpHMD simulations estimated the pK_a 's of 4.8–5.1 for the apo and fentanyl-bound mOR, thus suggesting that it remains deprotonated in the active mOR.

Having a solution pK_a of 6.5³³ and two neutral tautomer forms, histidine may sample all three protonation states in the protein environment at physiological pH 7.4. Our work demonstrates that the tautomer state of histidine in the ligand access region may alter the mechanism and possibly also the thermodynamics and kinetics of ligand binding. Thus, the conventional treatment in MD simulations, i.e., fixing histidine in a neutral tautomer state following the program default (HIE in Amber²⁸ and HID in CHARMM-GUI⁵²) may not be appropriate for detailed investigations.

By combining CpHMD titration to determine protonation states and fixed-charge simulations for long-time-scale conformational sampling, our work led to new and surprising findings; however, a major caveat of the study is that all other histidines have been fixed in one protonation state in the WE and equilibrium simulations, even though some of them may sample alternative protonation state at physiological pH according to the CpHMD titration. A more complete understanding of how protonation states impact the conformational dynamics and ligand binding of GPCRs awaits the development of GPU-accelerated hybrid-solvent^{22,23} and all-atom CpHMD methods⁵³ and their integration with enhanced sampling protocols such as the WE approach.^{19,21,54} We also note that the present work is based on the activated structure of mOR and does not explore the large conformational changes of the receptor, which likely occur on a much slower timescale, e.g., the activation time of the class A GPCR α_{2A} adrenergic receptor was estimated as 40 ms.⁵⁵ Notwithstanding the caveats, our detailed fentanyl-mOR interaction fingerprint analysis provides a basis for pharmacological investigations of fentanyl analogs, particularly how structural modifications

alter the binding properties of newly identified fentanyl derivatives which may have increased potency and abuse potential.

Supporting Information Available

Supplementary information contains Methods and Protocol, Supplemental Tables, and Supplemental Figures.

Acknowledgement This project was supported by FDA's Safety Research Interest Group and appointment to the Research Participation Programs at the Oak Ridge Institute for Science and Education through an interagency agreement between the Department of Energy and FDA. Financial support from the National Institutes of Health (GM09888) to J.S. and P.M. is acknowledged.

Disclaimer: The findings and conclusions in this manuscript have not been formally disseminated by the FDA and should not be construed to represent any agency determination or policy. The mention of commercial products, their sources, or their use in connection with material reported herein is not to be construed as either an actual or implied endorsement of such products by the Department of Health and Human Services.

Data Availability All data generated or analysed during this study are included in this published article and its supplementary information files.

References

- (1) CDC WONDER. <https://wonder.cdc.gov/>.
- (2) Synthetic Opioid Overdose Data | Drug Overdose | CDC Injury Center. <https://www.cdc.gov/drugoverdose/data/fentanyl.html>, 2020.
- (3) Van Bever, W. F.; Niemegeers, C. J.; Schellekens, K. H.; Janssen, P. A. N-4-Substituted 1-(2-Arylethyl)-4-Piperidinyl-N-Phenylpropanamides, a Novel Series of Extremely Potent Analgesics with Unusually High Safety Margin. *Arzneimittelforschung*. **1976**, *26*, 1548–1551.
- (4) Volpe, D. A.; Tobin, G. A. M.; Mellon, R. D.; Katki, A. G.; Parker, R. J.; Colatsky, T.; Kropp, T. J.; Verbois, S. L. Uniform Assessment and Ranking of Opioid Mu Receptor Binding Constants for Selected Opioid Drugs. *Regul. Toxicol. Pharmacol.* **2011**, *59*, 385–390.
- (5) Burns, S. M.; Cunningham, C. W.; Mercer, S. L. DARK Classics in Chemical Neuroscience: Fentanyl. *ACS Chem. Neurosci.* **2018**, *9*, 2428–2437.
- (6) Comer, S. D.; Cahill, C. M. Fentanyl: Receptor Pharmacology, Abuse Potential, and Implications for Treatment. *Neurosci. Biobehav. Rev.* **2019**, *106*, 49–57.
- (7) Vardanyan, R. S.; Hruby, V. J. Fentanyl-Related Compounds and Derivatives: Current Status and Future Prospects for Pharmaceutical Applications. *Future Med. Chem.* **2014**, *6*, 385–412.
- (8) Pathan, H.; Williams, J. Basic Opioid Pharmacology: An Update. *Br. J. Pain* **2012**, *6*, 11–16.
- (9) Huang, W.; Manglik, A.; Venkatakrishnan, A. J.; Laeremans, T.; Feinberg, E. N.; Sanborn, A. L.; Kato, H. E.; Livingston, K. E.; Thorsen, T. S.; Kling, R. C.; Granier, S.; Gmeiner, P.; Husbands, S. M.; Traynor, J. R.; Weis, W. I.; Steyaert, J.; Dror, R. O.; Kobilka, B. K. Structural Insights into μ -Opioid Receptor Activation. *Nature* **2015**, *524*, 315–321.
- (10) Manglik, A. Crystal Structure of the μ -Opioid Receptor Bound to a Morphinan Antagonist. *Nature* **2012**, *485*, 321.
- (11) Koehl, A.; Hu, H.; Maeda, S.; Zhang, Y.; Qu, Q.; Paggi, J. M.; Latorraca, N. R.; Hilger, D.; Dawson, R.; Matile, H.; Schertler, G. F. X.; Granier, S.; Weis, W. I.; Dror, R. O.; Manglik, A.; Skiniotis, G.; Kobilka, B. K. Structure of the μ -Opioid Receptor-Gi Protein Complex. *Nature* **2018**, *558*, 547–552.
- (12) Ballesteros, J. A.; Weinstein, H. Integrated Methods for the Construction of Three-Dimensional Models and Computational Probing of Structure-Function Relations in G Protein-Coupled Receptors. *Methods Neurosci.* **1995**, *25*, 366–428.
- (13) Surrat, C. K.; Johnson, P. S.; Moriwaki, A.; Seidleck, B. K.; Blaschak, C. J.; Wang, J. B.; Uhl, G. R. Charged Transmembrane Domain Amino Acids Are Critical for Agonist Recognition And Intrinsic Activity. *J. Biol. Chem.* **1994**, *269*, 20548–20553.
- (14) Mansour, A.; Taylor, L. P.; Fine, J. L.; Thompson, R. C.; Hoversten, M. T.; Mosberg, H. I.; Watson, S. J.; Akil, H. Key Residues Defining the μ -Opioid Receptor Binding Pocket: A Site-Directed Mutagenesis Study. *J. Neurochem.* **1997**, *68*, 344–353.
- (15) Meyer, J.; Del Vecchio, G.; Seitz, V.; Massaly, N.; Stein, C. Modulation of M -opioid Receptor Activation by Acidic pH Is Dependent on Ligand Structure and an Ionizable Amino Acid Residue. *Br. J. Pharmacol.* **2019**, *176*, 4510–4520.
- (16) Ellis, C. R.; Kruhlak, N. L.; Kim, M. T.; Hawkins, E. G.; Stavitskaya, L. Predicting Opioid Receptor Binding Affinity of Pharmacologically Unclassified Designer Substances Using Molecular Docking. *PLoS One* **2018**, *13*, e0197734.
- (17) Subramanian, G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson, D. M. Molecular Docking Reveals a Novel Binding Site Model for Fentanyl at the μ -Opioid Receptor. *J. Med. Chem.* **2000**, *43*, 381–391.
- (18) Lipiński, P. F. J.; Jarończyk, M.; Dobrowolski, J. C.; Sadlej, J. Molecular Dynamics of Fentanyl Bound to μ -Opioid Receptor. *J. Mol. Model.* **2019**, *25*, 144.
- (19) Huber, G.; Kim, S. Weighted-Ensemble Brownian Dynamics Simulations for Protein Association Reactions. *Biophys. J.* **1996**, *70*, 97–110.
- (20) Zwier, M. C.; Adelman, J. L.; Kaus, J. W.; Pratt, A. J.; Wong, K. F.; Rego, N. B.; Suárez, E.; Lettieri, S.; Wang, D. W.; Grabe, M.; Zuckerman, D. M.; Chong, L. T. WESTPA: An Interoperable, Highly Scalable Software Package for Weighted Ensemble Simulation and Analysis. *J. Chem. Theory Comput.* **2015**, *11*, 800–809.
- (21) Zuckerman, D. M.; Chong, L. T. Weighted Ensemble Simulation: Review of Methodology, Applications, and Software. *Annu. Rev. Biophys.* **2017**, *46*, 43–57.
- (22) Wallace, J. A.; Shen, J. K. Continuous Constant pH Molecular Dynamics in Explicit Solvent with pH-Based Replica Exchange. *J. Chem. Theory Comput.* **2011**, *7*, 2617–2629.
- (23) Huang, Y.; Chen, W.; Dotson, D. L.; Beckstein, O.; Shen, J. Mechanism of pH-Dependent Activation of the Sodium-Proton Antiporter NhaA. *Nat. Commun.* **2016**, *7*, 12940.
- (24) Huang, Y.; Henderson, J. A.; Shen, J. Continuous constant pH Molecular Dynamics Simulations of Transmembrane Proteins. *Methods Mol. Biol.* **2020**, in press.
- (25) Chen, W.; Huang, Y.; Shen, J. Conformational Activation of a Transmembrane Proton Channel from Constant pH Molecular Dynamics. *J. Phys. Chem. Lett.* **2016**, *7*, 3961–3966.
- (26) Yue, Z.; Chen, W.; Zgurskaya, H. I.; Shen, J. Constant pH Molecular Dynamics Reveals How Proton Release Drives the Conformational Transition of a Transmembrane Efflux Pump. *J. Chem. Theory Comput.* **2017**, *13*, 6405–6414.
- (27) Henderson, J. A.; Huang, Y.; Beckstein, O.; Shen, J. Alternative Proton-Binding Site and Long-Distance Coupling in *Escherichia Coli* Sodium-Proton Antiporter NhaA. *Proc. Natl. Acad. Sci. USA* **2020**, *117*, 25517–25522.
- (28) Case, D. A.; Ben-Shalom, I. Y.; Brozell, S. R.; Cerutti, D. S.; Cheatham, T. E. I.; Cruzeiro, V. W. D.; Darden, T. A.; Duke, R. E.; Ghoreishi, D.; Gilson, M. K. AMBER 2018. 2018.
- (29) Yuan, S.; Vogel, H.; Filipek, S. The Role of Water and Sodium Ions in the Activation of the μ -Opioid Receptor. *Angew. Chem. Int. Ed.* **2013**, *52*, 10112–10115.
- (30) Katritch, V.; Fenalti, G.; Abola, E. E.; Roth, B. L.; Cherezov, V.; Stevens, R. C. Allosteric Sodium in Class A GPCR Signaling. *Trends Biochem. Sci.* **2014**, *39*, 233–244.
- (31) Cong, X.; Campomanes, P.; Kless, A.; Schapitz, I.; Wagener, M.; Koch, T.; Carloni, P. Structural Determinants for the Binding of Morphinan Agonists to the μ -Opioid Receptor. *PLOS ONE* **2015**, *10*, e0135998.
- (32) Schneider, S.; Provasi, D.; Filizola, M. How Oliceridine (TRV-130) Binds and Stabilizes a μ -Opioid Receptor Conformational State That Selectively Triggers G Protein Signaling Pathways. *Biochemistry* **2016**, *55*, 6456–6466.
- (33) Thurkill, R. L.; Grimsley, G. R.; Scholtz, J. M.; Pace, C. N. pK values of the ionizable groups of proteins. *Protein Sci.* **2006**, *15*, 1214–1218.
- (34) Maguire, P.; Tsai, N.; Cometta-Morini, C.; Loew, G. Pharmacological Profiles of Fentanyl Analogs at Mu, Delta and Kappa Opiate Receptors. *Eur. J. Pharmacol.* **1992**, *213*, 219–225.
- (35) Casy, A. F.; Huckstep, M. R. Structure-Activity Studies of Fentanyl. *J. Pharm. Pharmacol.* **1988**, *40*, 605–608.
- (36) Lipiński, P. F. J.; Kosson, P.; Matalińska, J.; Roszkowski, P.; Czarnocki, Z.; Jarończyk, M.; Misicka, A.; Dobrowolski, J. C.; Sadlej, J. Fentanyl Family at the μ -Opioid Receptor: Uniform Assessment of Binding and Computational Analysis. *Molecules* **2019**, *24*, 740.
- (37) Willett, P.; Barnard, J. M.; Downs, G. M. Chemical Similarity Searching. *J. Chem. Inf. Comput. Sci.* **1998**, *38*, 983–996.
- (38) Chaturvedi, K.; Shahrestanifar, M.; Howells, R. D. μ Opioid Receptor: Role for the Amino Terminus as a Determinant of Ligand Binding Affinity. *Mol. Brain Res.* **2000**, *76*, 64–72.
- (39) United Nations Office on Drugs and Crime. *Fentanyl and Its Analogues – 50 Years On*; Global Smart Update, 2017.
- (40) Debiec, K. T.; Cerutti, D. S.; Baker, L. R.; Gronenborn, A. M.; Case, D. A.; Chong, L. T. Further along the Road Less Traveled: AMBER Ff15ipq, an Original Protein Force Field Built on a Self-Consistent Physical Model. *J. Chem. Theory Comput.* **2016**, *12*, 3926–3947.
- (41) Best, R. B.; Zhu, X.; Shim, J.; Lopes, P. E. M.; Mittal, J.; Feig, M.; Mackerell, A. D. Optimization of the Additive CHARMM All-Atom

- Protein Force Field Targeting Improved Sampling of the Backbone ϕ , ψ and Side-Chain χ_1 and χ_2 Dihedral Angles. *J. Chem. Theory Comput.* **2012**, *8*, 3257–3273.
- (42) Huang, J.; Rauscher, S.; Nawrocki, G.; Ran, T.; Feig, M.; de Groot, B. L.; Grubmüller, H.; MacKerell, A. D. CHARMM36m: An Improved Force Field for Folded and Intrinsically Disordered Proteins. *Nat. Methods* **2017**, *14*, 71–73.
- (43) Suárez, E.; Lettieri, S.; Zwier, M. C.; Stringer, C. A.; Subramanian, S. R.; Chong, L. T.; Zuckerman, D. M. Simultaneous Computation of Dynamical and Equilibrium Information Using a Weighted Ensemble of Trajectories. *J. Chem. Theory Comput.* **2014**, *10*, 2658–2667.
- (44) Spahn, V.; Vecchio, G. D.; Labuz, D.; Rodriguez-Gaztelumendi, A.; Massaly, N.; Temp, J.; Durmaz, V.; Sabri, P.; Reidelbach, M.; Machelska, H.; Weber, M.; Stein, C. A Nontoxic Pain Killer Designed by Modeling of Pathological Receptor Conformations. *Science* **2017**, *355*, 966–969.
- (45) Spahn, V.; Del Vecchio, G.; Rodriguez-Gaztelumendi, A.; Temp, J.; Labuz, D.; Klöner, M.; Reidelbach, M.; Machelska, H.; Weber, M.; Stein, C. Opioid Receptor Signaling, Analgesic and Side Effects Induced by a Computationally Designed pH-Dependent Agonist. *Sci. Rep.* **2018**, *8*, 8965.
- (46) Roy, S. D.; Flynn, G. L. Solubility Behavior of Narcotic Analgesics in Aqueous Media: Solubilities and Dissociation Constants of Morphine, Fentanyl, and Sufentanil. *Pharm. Res.* **1989**, *6*, 147–151.
- (47) Thurkill, R. L.; Cross, D. A.; Scholtz, J. M.; Pace, C. N. pKa of Fentanyl Varies With Temperature: Implications for Acid-Base Management During Extremes of Body Temperature. *J. Cardiothorac. Vasc. Anesth.* **2005**, *19*, 759–762.
- (48) Rosas, R.; Huang, X.-P.; Roth, B. L.; Dockendorff, C. β -Fluorofentanyls Are pH-Sensitive μ Opioid Receptor Agonists. *ACS Med. Chem. Lett.* **2019**, *10*, 1353–1356.
- (49) Chan, H. C. S.; Wang, J.; Palczewski, K.; Filipek, S.; Vogel, H.; Liu, Z.-J.; Yuan, S. Exploring a New Ligand Binding Site of G Protein-Coupled Receptors. *Chem. Sci.* **2018**, *9*, 6480–6489.
- (50) Vickery, O. N.; Carvalheda, C. A.; Zaidi, S. A.; Pislakov, A. V.; Katritch, V.; Zachariae, U. Intracellular Transfer of Na⁺ in an Active-State G-Protein-Coupled Receptor. *Structure* **2018**, *26*, 171–180.e2.
- (51) Alexov, E.; Mehler, E. L.; Baker, N.; Baptista, A.; Huang, Y.; Milletti, F.; Nielsen, J. E.; Farrell, D.; Carstensen, T.; Olsson, M. H. M.; Shen, J. K.; Warwicker, J.; Williams, S.; Word, J. M. PROGRESS IN THE PREDICTION OF pKa VALUES IN PROTEINS. *Proteins* **2011**, *79*, 3260–3275.
- (52) Lee, J.; Cheng, X.; Swails, J. M.; Yeom, M. S.; Eastman, P. K.; Lemkul, J. A.; Wei, S.; Buckner, J.; Jeong, J. C.; Qi, Y.; Jo, S.; Pande, V. S.; Case, D. A.; Brooks, C. L.; MacKerell, A. D.; Klauda, J. B.; Im, W. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. *J. Chem. Theory Comput.* **2016**, *12*, 405–413.
- (53) Huang, Y.; Chen, W.; Wallace, J. A.; Shen, J. All-Atom Continuous Constant pH Molecular Dynamics With Particle Mesh Ewald and Titratable Water. *J. Chem. Theory Comput.* **2016**, *12*, 5411–5421.
- (54) Zwier, M. C.; Kaus, J. W.; Chong, L. T. Efficient Explicit-Solvent Molecular Dynamics Simulations of Molecular Association Kinetics: Methane/Methane, Na⁺/Cl⁻, Methane/Benzene, and K⁺/18-Crown-6 Ether. *J. Chem. Theory Comput.* **2011**, *7*, 1189–1197.
- (55) Vilardaga, J.-P.; Bünemann, M.; Krasel, C.; Castro, M.; Lohse, M. J. Measurement of the Millisecond Activation Switch of G Protein-Coupled Receptors in Living Cells. *Nat. Biotechnol.* **2003**, *21*, 807–812.